---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-066553"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2023-11-29T23:59:59+00:00"
generated_at: "2026-06-07T20:27:39.514915+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics dosed first participants in Phase 1 trial of SAB-142 for Type 1 Diabetes

## Summary
- First-in-human Phase 1 trial dosed in Australia; double-blind, placebo-controlled, single-ascending dose design.
- SAB-142 is a first-in-class fully-human anti-thymocyte immunoglobulin targeting immune cells that destroy pancreatic beta cells.
- Phase 1 assesses safety, tolerability, PK/PD, and aims to establish proof of biological activity in T1D.
- Company plans to file IND with FDA and CTA in UK/EU in 2024 to advance to Phase 2b study.
- Trial led by Dr. Kristi McLendon at Nucleus Network; SAB-142 has potential as disease-modifying treatment for T1D.

## SEC filing metadata
- accession: 0000950170-23-066553
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2023-11-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017023066553/0000950170-23-066553-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017023066553/sabs-20231129.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-066553
- JSON: https://secwatch.observer/filing/0000950170-23-066553.json
- Plain text: https://secwatch.observer/filing/0000950170-23-066553.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.